Recursion Pharmaceuticals, Inc. RXRX
We take great care to ensure that the data presented and summarized in this overview for RECURSION PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RXRX
View all-
Vanguard Group Inc Valley Forge, PA36.1MShares$204 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33MShares$186 Million1.38% of portfolio
-
Baillie Gifford & CO24MShares$135 Million0.09% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$97.8 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$82.9 Million0.31% of portfolio
-
Kinnevik Ab (Publ) Stockholm, V713.4MShares$75.9 Million100.0% of portfolio
-
State Street Corp Boston, MA11.2MShares$63.2 Million0.0% of portfolio
-
Novo Holdings Hellerup, G79.67MShares$54.6 Million4.26% of portfolio
-
Mic Capital Management Uk LLP London, X09.64MShares$54.5 Million12.97% of portfolio
-
Nikko Asset Management Americas, Inc.8.17MShares$46.1 Million0.44% of portfolio
Latest Institutional Activity in RXRX
Top Purchases
Top Sells
About RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Insider Transactions at RXRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 23
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$500,000
$5.7 P/Share
|
|
Oct 23
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Oct 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Oct 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.31%
|
$600,000
$6.04 P/Share
|
|
Oct 10
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
120,000
+10.05%
|
-
|
|
Oct 01
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,941
+2.08%
|
-
|
|
Oct 01
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,961
+0.16%
|
-
|
|
Sep 25
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$400,000
$4.76 P/Share
|
|
Sep 25
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Sep 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,057
-0.87%
|
$28,228
$4.83 P/Share
|
|
Sep 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Sep 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.31%
|
$400,000
$4.71 P/Share
|
|
Sep 10
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
120,000
+10.05%
|
-
|
|
Aug 26
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$400,000
$4.84 P/Share
|
|
Aug 26
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Aug 18
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Open market or private sale
|
Direct |
36,599
-5.19%
|
$182,995
$5.52 P/Share
|
|
Aug 15
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,789
-0.53%
|
$18,945
$5.64 P/Share
|
|
Aug 15
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
40,390
-4.06%
|
$201,950
$5.64 P/Share
|
|
Aug 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,908
-1.45%
|
$59,540
$5.64 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
117,875
-100.0%
|
$589,375
$5.28 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.51M shares |
|---|---|
| Conversion of derivative security | 1.28M shares |
| Exercise of conversion of derivative security | 78.8K shares |
| Open market or private sale | 1.53M shares |
|---|---|
| Payment of exercise price or tax liability | 278K shares |
| Bona fide gift | 50K shares |